-
Online now: Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS).
#mmsm @theMMRF @IMFmyeloma @myelomacrowdhttps://www.nature.com/articles/s41375-020-0718-z … -
We just published our Phase I/II study of carfilzomib, bendamustine and dex in newly diagnosed myeloma with 100% ORR (89% VGPR, 63%CR). CD34 collection was not impaired. High ORR and cost-effective
@VincentRK@AmgenOncology@columbiacancer#mmsm https://www.nature.com/articles/s41408-020-0278-5 … -
We don’t propose indefinite rev in the paper. However, what is the cost of treating a fracture or renal failure?
#mmsm https://twitter.com/bijoytelivala/status/1225173883453673472 … -
New article: PHLPP Sensitizes Multiple Myeloma Cells to Bortezomib Through Regulating LAMP2. http://bit.ly/3bjg0H9
#MMSM#MultipleMyeloma#hematology -
New article: Donor Lymphocyte Infusions After Allogeneic Transplantation: A Single-Center Experience. http://bit.ly/2v8YIvQ
#MMSM#MultipleMyeloma#hematology -
Read the conclusion. The trial used Len continuous like maintenance. Our conclusion was 2 years in the paper to match the Spanish group
#mmsm https://twitter.com/bijoytelivala/status/1225177408170528769 …
-
T4 Other approaches
#mmsm -
T3 DETER: studying MRD rates after 1 and 2 yr on treatment. Comparing flow and NGS
#mmsm -
T3 DETER trial-focusing on high risk SMM only. 2yr total treatment. 288 participants NCT03937635
#mmsm -
T3 EAA173: 1. does adding dara to L + D boost response rate,slow down progression? 2. Dex for 1 year -increase response?
#mmsm -
T2 E3A06 benefited high risk SMM. Low risk probably can continue on observation
#mmsm -
T2 E3A06 rx-len 25 mg days 1-21 indefinitely vs observation. At 3 yrs, PFS 91% in Len group, 66% in observation
#mmsm -
T2 E3A06 asked if you need dex at all. Used MRI to exclude pts with true MM; 244 pts in all
#mmsm -
T2 QUIRIDEX 119 pts PFS, Survival benefit for SMM rx up to 2 yr of len with dex HR 0.28 doi: 10.1016/S1470-2045(16)30124-3
#mmsm -
20/20/20 or 20/2/30 means >20% PC in marrow, >2g/dl M spike, FLC ratio>20; if 2 or more, average 29 mo to MM progression
#mmsm -
more than 20% PC in marrow, >2g/dl M spike, Free light chain ratio >20
#mmsm -
T1 20/20/20 rule for high risk SMM likely to be new standard (Lakshman Blood Can J 2018 8:59)
#mmsm -
T1 Spanish Def: 95% CD19-/dim CD 45-/dim CD38low CD 56high AND with immunoparesis and/or >2g/dl of IgA or 1g proteinuria
#mmsm -
What is proteinuria?
#MMSM
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.